Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-02, Stock:ABBV, The news for the past five days is as follows:
2018-03-23: NEWS1: Is AbbVie &apos;Unraveling&apos; In Solid Tumor Market After Drug Misstep?.NEWS2: Pharma Stock Roundup: ABBV&apos;s Rova-T Disappoints, J&J Unit Gets Buyout Offer.NEWS3: Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus.NEWS4: Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus.NEWS5: 5 Dividend Aristocrats Where Analysts See Capital Gains.NEWS6: 5 Dividend Aristocrats Where Analysts See Capital Gains.NEWS7: Cancer Space Roundup: NVS&apos; Tasigna & SGEN&apos;s Adcetris Label Expansions in Focus.NEWS8: Is AbbVie Still a Buy After Its Rova-T Setback?.NEWS9: Is AbbVie Still a Buy After Its Rova-T Setback?.NEWS10: The Implied Analyst 12-Month Target For SPMO.NEWS11: The Implied Analyst 12-Month Target For SPMO.NEWS12: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS13: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS14: How Gilead Sciences’ Ranexa, AmBisome, Zydelig, and Vosevi Performed.NEWS15: Is AbbVie Still a Buy After Its Rova-T Setback?.NEWS16: AbbVie: Biggest Loss in the S&P 500 on March 22.NEWS17: AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal.NEWS18: AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal.NEWS19: Today’s Research Reports on Stocks to Watch: AbbVie and Pfizer.NEWS20: AbbVie’s latest trial data was probably worse than it looked.NEWS21: AbbVie’s latest trial data was probably worse than it looked.NEWS22: AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome.NEWS23: Is The AbbVie Dip A Buying Opportunity?.NEWS24: Asian shares slump on fears of trade war between US, China.NEWS25: Asian shares slump on fears of trade war between US, China.NEWS26: Is It Game Over for AbbVie's Promising Cancer Drug?.NEWS27: Is It Game Over for AbbVie's Promising Cancer Drug?.NEWS28: Is It Game Over for AbbVie&apos;s Promising Cancer Drug?.NEWS29: AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu.
2018-03-26: NEWS1: U.S. jury orders AbbVie to pay $3 mln in AndroGel retrial.NEWS2: The Biggest Movers: Microsoft Shines; AbbVie Slumps.NEWS3: Monday's ETF with Unusual Volume: XMX.NEWS4: Monday's ETF with Unusual Volume: XMX.NEWS5: Exploring Xencor’s Cash Flows.NEWS6: Analysts’ Recommendations for Xencor and Its Peers in March.NEWS7: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.NEWS8: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.NEWS9: The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer.
2018-03-27: NEWS1: How Risky Is AbbVie's Pipeline?.NEWS2: How Risky Is AbbVie's Pipeline?.NEWS3: How Risky Is AbbVie&apos;s Pipeline?.
2018-03-28: NEWS1: Bristol-Myers Squibb’s Valuation in March 2018.NEWS2: Bristol-Myers Squibb’s Valuation in March 2018.NEWS3: When Will They Learn? 4 Huge Biotech Blowups.NEWS4: When Will They Learn? 4 Huge Biotech Blowups.NEWS5: When Will They Learn? 4 Huge Biotech Blowups.NEWS6: AbbVie a Top Ranked SAFE Dividend Stock With 4.2% Yield (ABBV).NEWS7: AbbVie a Top Ranked SAFE Dividend Stock With 4.2% Yield (ABBV).NEWS8: It's Not Final 4 But WashU, Wisconsin Fight on Other Court.NEWS9: 3 Biotechs That Could Get Big Boosts in April.NEWS10: Validea Peter Lynch Strategy Daily Upgrade Report - 3/28/2018.NEWS11: Validea Peter Lynch Strategy Daily Upgrade Report - 3/28/2018.NEWS12: Biotech Stocks Facing FDA Decision In April.NEWS13: Biotech Stocks Facing FDA Decision In April.
2018-03-29: NEWS1: Geron Corp. Skyrocketed and AbbVie Inc. Crashed -- Are These Stocks Buys?.NEWS2: Analysts’ Ratings for Sorrento and Its Peers in March 2018.NEWS3: Analysts’ Ratings for Sorrento and Its Peers in March 2018.NEWS4: How AbbVie’s Cash Flows Have Trended.NEWS5: What to Expect from AbbVie in 2018.NEWS6: How AbbVie’s Cash Flows Have Trended.NEWS7: What to Expect from AbbVie in 2018.NEWS8: How Has AbbVie Performed Financially?.NEWS9: Analyzing AbbVie’s Endocrinology Portfolio.NEWS10: Analyzing AbbVie’s Endocrinology Portfolio.NEWS11: How Has AbbVie Performed Financially?.NEWS12: A Look at AbbVie’s Product Portfolio.NEWS13: What Analysts Recommend for AbbVie and Peers in March 2018.NEWS14: A Look at AbbVie’s Product Portfolio.NEWS15: What Analysts Recommend for AbbVie and Peers in March 2018.NEWS16: AbbVie Has a Growing Credibility Problem.NEWS17: AbbVie Has a Growing Credibility Problem.NEWS18: How Is Novartis’s Cosentyx Positioned after 4Q17?.NEWS19: How Is Novartis’s Cosentyx Positioned after 4Q17?.NEWS20: What Analysts Recommend for Merck in March 2018.NEWS21: How Bristol-Myers Squibb’s Virology Drugs Performed in 4Q17.NEWS22: How Bristol-Myers Squibb’s Virology Drugs Performed in 4Q17.

Answer: Decrease